In view of the above considerations, the aim of the present study was to evaluate the immunohistochemical PXR expression in invasive breast carcinoma in association with multiple clinicopathological characteristics: ER, PR, and HER2 expression, tumor cells’ proliferative capacity, as well as overall disease-free patients’ survival. This evidence concerns the gene NR1I2 and neoplasm.